Enzo Biochem traded at $1.20 this Tuesday April 9th. Looking back, over the last four weeks, Enzo Biochem lost 8.40 percent. Over the last 12 months, its price fell by 53.67 percent. Looking ahead, we forecast Enzo Biochem to be priced at 1.16 by the end of this quarter and at 1.06 in one year, according to Trading Economics global macro models projections and analysts expectations.
Enzo Biochem, Inc. (Enzo) is an integrated diagnostics, clinical lab, and life sciences company that is focused on delivering and applying advanced technology to produce reliable products and services for clinical needs. The Company develops, manufactures and sells technology solutions and platforms to clinical laboratories, specialty clinics, researchers and physicians globally. Enzo's segments include Enzo Clinical Lab, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Lab is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. Enzo Life Sciences manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. Enzo Therapeutics is a biopharmaceutical venture that developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.